Response to the HEPLISAV-B Hepatitis B Vaccine in Treatment Naive Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's -Tyrosine Kinase Inhibitor (BTK-I)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

17 Dec 2020 Status changed from recruiting to completed.
01 Dec 2020 Results (n=121) of two studies (NCT03685708 (Hep-CpG) and NCT03702231 (RZV)) assessing effect of BTKi's on de novo immune response against recombinant hepatitis B vaccine and recall response against recombinant zoster vaccine in chronic lymphocytic leukemia patients who were treatment naive or on Bruton's -Tyrosine Kinase Inhibitor, published in the Blood.
20 Aug 2020 Planned number of patients changed from 123 to 108.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com